

16 April 2025

ASX Market Announcements
ASX Limited
Level 4
Stock Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

RESULTS OF GENERAL MEETING

Respiri Limited (ASX:RSH; OTCQB:RSHUF) ("Respiri" or the "Company"), hereby provides the results of its general meeting of shareholders held on 16 April 2025.

Information required to be disclosed by the Company in accordance with Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act is attached.

All resolutions were passed on a poll. Details of resolutions, the proxies received, and the votes cast on the poll in respect of each resolution are set out in the attached results summary.

For and on behalf of the Board:

Respiri Limited

JUSTIN MOUCHACCA
Company Secretary

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management and Remote Patient Monitoring services. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia and in New York, USA.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link <https://wheezo.com>

wheezo® is a registered trademark of Respiri Limited.

Respiri Limited
2025 General Meeting
Wednesday, 16 April 2025 - Voting Results

The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth)

Resolution Details			Show of Hands (S) or Poll (P)	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
Resolution		Resolution Type	S or P	For	Against	Proxy's Discretion	Abstain/ Excluded	For	Against	Abstain	Carried/ Not Carried
1.	Change of Company Name	Special	P	462,495,934 99.74%	637,447 0.14%	559,260 0.12%	977,020	467,266,854 99.86%	637,447 0.14%	977,020	Carried
2.	Ratification and approval of prior issue of Shares	Ordinary	P	448,511,832 99.60%	1,275,138 0.28%	559,260 0.12%	14,323,431	453,282,752 99.72%	1,275,138 0.28%	14,323,431	Carried
3.	Approval to issue Tranche 2 Placement Shares	Ordinary	P	449,316,832 99.58%	1,346,388 0.30%	559,260 0.12%	13,447,181	454,087,752 99.70%	1,346,388 0.30%	13,447,181	Carried
4.	Approval of Issue of Placement Shares to Mr Nicholas Smedley, Director of the Company	Ordinary	P	460,774,344 99.23%	3,147,715 0.68%	433,121 0.09%	314,481	465,358,915 99.33%	3,147,715 0.67%	314,481	Carried
5.	Approval of Issue of Placement Shares to Mr Marjan Mikel, Director of the Company	Ordinary	P	460,859,725 99.24%	3,118,315 0.67%	433,121 0.09%	258,500	465,444,296 99.33%	3,118,315 0.67%	258,500	Carried

*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

For personal use only